Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma

Clinical trial NCT03966118 · UNKNOWN

Trial details

NCT number: NCT03966118
Sponsor: P. C. Thuss-Patience
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Gastroesophageal Junction Adenocarcinoma Adenocarcinoma of the Stomach

Start date: 2019-04-01
Primary completion: 2022-09-01
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.